Please type a plus sign (+) inside this box

Please type a plus sign (+) inside this box

UTILITY

UTILITY PATENT APPLICATION TRANSMITTAL

o a collec	tion of information	unless it displays a valid OMB control number			
Attorney Docket No.		38-21(51770)B			
First In	ventor	Fincher, Karen L.			
Title	NUCLEIC ACII ASSOCIATED V	MOLECULES AND OTHER MOLECULES VITH PLANTS			
_		FI 0325///1901/S			

TRANSMITTAL	Title NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH PLANTS					
(b))	Express Mail Label No. EL032544180US					
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application content.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231					
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submu an original and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)					
2. Applicant claims small entity status. 3. X Specification [Total Pages 69] (preferred arrangement set forth below) - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R and D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. X Computer Readable Form (CFR) b. Specification Sequence Listing on: i. X CD-ROM or CD-R (2 copies); or ii. Paper c. X Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet document(s))					
- Claim(s) - Abstract of the Disclosure 4. Drawing(s) (35 USC 113) [Total Sheets	10. 37 CFR 3.73(b) Statement (when there is an assignee) X Power of Attorney					
5. Oath or Declaration [Total Pages 3	11 English Translation Document (if applicable) 12. X Information Disclosure					
a. X Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	13. Preliminary Amendment 14. X Return Receipt Postcard (MPEP 503) (should be specifically itemized) 15. Certified Copy of Priority Document (s) (if foreign priority is claimed) 16 Request and Certification under 35 U.S.C. 122					
6. Application Data Sheet. See 37 CFR 1.76	(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other:					
18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No: Prior Application Information: Examiner: Group/Art Unit For CONTINUATION OR DIVISIONAL APPS ONLY The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts 19. CORRESPONDENCE ADDRESS						
Customer Number or Bar Code Label (Insert Eustomer No. or anach Bar Code or X Correspondence address below						
Name Lawrence M. Lavin, Jr.						
Patent Department, E2NA; Monsan	to Company					
Address 800 N. Lindbergh Boulevard						
City St. Louis Country USA	State Missouri ZIP CODE 63167 Telephone (314) 694-3602 FAX (314) 694-1671					
Name (Print/Type) Lawrence M. Lavin, Jr.						
G:	Registration No. (Attorney/Agent) 30768 by Jian S. Zhou (Reg. No. 41422) Date: 12/08/2000					

Burden Hour Statement. This form is estimated to take 2 hours to complete. Time will vary depending pon the needs of the individual cases. Any comments on the amount of time you required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

U...S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fee are subject to annual revision.

l	Comple	ete if Known
	Application Number	
I	Filing Date	
	First Named Inventor	Fincher, Karen L.
I	Examiner Name	
4	Group Art Unit	
١	Attorney Docket No.	38-21(51770)B

TOTAL AMOUNT OF PAYMENT (\$) 710		Attorney Docket No.			No. 38-21(51770)B	38-21(51770)B	
METHOD OF PAYMENT (check one)							
1 The Commissioner is hereby authorized to charge		DITIO	NAL	FEES			
Deposit Deposit	Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description Fee Pa	uid	
Account Number 13-4125	105	130	205	65	Surcharge - late filing fee or oath 0		
Deposit Account	127	50	227	25	Surcharge - late provisional filing fee or cover she	=	
Name Charge Any Additional Fee Required	139	130	139	130	Non-English specification 0	=	
Charge Any Additional Fee Required under 37 CFR 1.16 and 1.17	147	2,520	147	2,520	For filing a request for ex part reexamination 0	=	
Applicant claims small entity status.	112	920*	112	1,840*	Requesting publication of SIR prior to Examiner action 0		
☐ See 37 CFR 1.27	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action 0		
2. Payment Enclosed:	115	110	215	55	Extension for reply within first month 0	\exists	
Check Credit card Order Other	116	380	216	190	Extension for reply within second month 0		
FEE CALCULATION T, BASIC FILING FEE	117	870	217	435	Extension for reply within third month 0		
	118	1,360	218	680	Extension for reply within fourth month 0		
Fee Fee Fee Fee Foo deceriation	128	1,850	228	925	Extension for reply within fifth month 0		
Code (\$) Code (\$) 101 710 201 355 Utility filing fee 710	119	300	219	150	Notice of Appeal 0		
101 710 201 355 Utility filing fee 710 106 320 206 160 Design filing fee	120	300	220	150	Filing a brief in support of an appeal 0		
107 490 207 245 Plant filing fee	121	260	221	150	Request for Oral hearing 0		
108 710 208 355 Reissue filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding 0		
114 150 214 75 Provisional filing fee	140	110	240	55	Petition to revive - unavoidable 0		
SUBTOTAL (1) (\$) 710 EXECUTE: Fee from		1,210	241	605	Petition to revive - unintentional 0		
		1,210	242	605	Utility issue fee (or reissue)		
Extra Clams below Fee Paid	143	430	243	215	Design issue fee 0		
Total Claims $9 \cdot 20** = -11 \times 18 = 0$ Todependent Claims $3 \cdot 3** = 0 \times 80 = 0$	144	430	243	215	Plant issue fee 0	_	
Multiple Dependent Multiple Dependent 270 = 0	122	130	122	130	Petitions to commissioner 0		
** or number previously paid, if greater; For reissues, see below	123	50	123	50	Processing under 37 CFR 1.17(q) 0	\Box [
Large Entity Small Entity	126	240	126	240	Submission of information Disclosure Statement 0		
Fee Fee Fee Fee description Code (\$) Code (\$)	581	40	581	40	Recording each patent assignment per property (times number of properties)		
103 18 203 9 Claims in excess of 20	146	690	246	345	Filing a submission after final rejection (37 CFR §1.129(a))		
102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claims, if not paid	149	690	249	345	For each additional invention to be examined 0	— I	
109 80 209 40 ** Reissue independent claims	179	690	279	345	(37 CFR §1.129(b)) Request for continued Examination (RCE)		
over original patent 110 18 210 9 ** Reissue claims in excess of 20	169	900	169	900		<u> </u>	
and over original patent				900	Request for expedited examination 0 of a design application	_	
SUBTOTAL (2) (\$) 0	Other	fee (speci	ту)				
** or number previously paid, if greater; For reissues, see abive	*Reduc	ed by Bas	ic Filinį	g Fee Paid	d SUBTOTAL (3) (\$)	0	
SUBMITTED BY Complete (if applicable)							
Name (Print/Type) Lawrence M. Lavin, Jr.	Reg	/		Attorney	y/Agent) 30768 Telephone (314) 694-36	i02	
Signature Lauvence M L.	1. 1	2/	111	1	1. 5 76 . De 12/0/2	0 -	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

Docket No.: 38-21(51770)B Inventor: Karen L. Fincher

Page 1 of 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Karen L. Fincher

Appln. No.: To Be Assigned

Filed:

For:

Nucleic Acid Molecules and Other

Molecules Associated with Plants

Art Unit:

To Be Assigned

Examiner:

To Be Assigned

Atty. Docket: 38-21(51770)B



I hereby verify this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No.EL032544180US on the date indicated and is addressed to: Commissioner for Patents, Washington, D.C. 20231

Jian S. Zhou

Registration No. 41, 422

TRANSMITTAL OF NON-PROVISIONAL PATENT APPLICATION

Commissioner for Patents

Box Patent Application

Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the complete patent application of:

Nucleic Acid Molecules and Other Molecules Associated with Plants

Inventors: Karen L. Fincher

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. Utility Patent Application Transmittal (PTO/SB/05);
- **2.** Form PTO/SB/17 (in duplicate);
- 3. U.S. Utility Patent Application entitled:

Nucleic Acid Molecules and Other Molecules Associated with Plants

and naming as inventors:

Karen L. FINCHER

the application consisting of:

- a. A specification containing:
 - (i) 67 pages of a description prior to the claims;
 - (ii) <u>1</u> pages of claims (9 claims); and
 - (iii) a one (1) page abstract;
- 4. The computer readable form (CRF) containing the sequence listing information;
- 5. 2 CD-Rs (Copy 1, Copy 2) containing the Sequence Listing;
- 6. Statement Regarding Sequence Submission;
- 7. Combined Declaration and Power of Attorney, executed by inventor Karen L. Fincher (3 pages);
- 8. Form PTO/SB/35
- 9. An Information Disclosure Statement;
- 10. Form PTO-1449 (1 page), with 8 accompanying documents; and
- 11. One (1) return postcard.

Docket No.: 38-21(51770)B Inventor: Karen L. Fincher

Page 3 of 3

It is respectfully requested that the attached prepaid postcard be stamped with the filing date and unofficial application number and returned to us as soon as possible.

Respectfully submitted,

Lawrence M. Lavin, Jr., Esq (Reg. No. 30,768)

Jian S. Zhou (Reg. No. 41,422)

Enclosures

Date: December 8, 2000

Patent Department, E2NA Monsanto Company 800 N. Lindbergh Boulevard St. Louis, MO 63167

Tel: 636-694-3602 Fax: 636-694-1671 Express Mail Label No.: EL 032544 180 US

PTO/SB/35 (11-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)

I.	Named Inventor	Karen L. Fincher	
Title	Nucleic A Molecules	cid Molecules and Othe Associated With Plant	r
	Oocket Number	,	

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

December 8, 2000

Signature

Jian S. Zhou, Reg.No. 41,422

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).